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CASE REPORT
We report a case of a 2-year-old boy presenting with persistent fever and splenomegaly who fulfilled the diagnostic criteria for haemophagocytic 
lymphohistiocytosis (HLH) according to the Histiocyte Society (2004). The persistence of a cardiac murmur despite multiple transfusions, 
and therapy which rendered him afebrile, led us to do an echocardiogram as part of surveillance for sepsis. This revealed tricuspid vegetation 
and a small ventricular septal defect. Blood culture and postoperative histology of the anterior leaflet of the tricuspid valve confirmed 
Streptococcus pneumoniae infection. The patient was successfully treated with intravenous antibiotic therapy for 6 weeks and dexamethasone 
for 8 weeks and remains well and in remission (from HLH) a year later with residual tricuspid regurgitation awaiting tricuspid valve 
replacement. 
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Haemophagocytic lymphohistiocytosis (HLH) is a reactive 
disorder resulting in generalised proliferation of histiocytes which 
phagocytose erythrocytes, platelets, leukocytes and their precursors. 
In addition, high levels of cytokines are produced which result in 
excessive activation of monocytes. The condition is also characterised 
by impaired natural killer cell function.1
Primary HLH is a familial disorder with an autosomal recessive 
inheritance pattern.  Dysregulation of the natural killer cell and T 
cell functioning of the immune system are responsible for the clinical 
syndrome seen in HLH. Currently 5 genetic loci are identified, each 
resulting in a different subtype of the disease. The gene product of 
each of these genes is involved in cytotoxic natural killer and T cell 
function of the immune system.2 Secondary HLH is an acquired 
disorder due activation of the immune system by an infection, 
malignancy and rarely collagen vascular disease.1
There is a wide repertoire of microbials which can precipitate HLH. 
This primarily includes viral agents: Epstein-Barr virus, human 
herpes virus 6, cytomegalovirus, adenovirus, parvovirus B19, varicella, 
measles, hepatitis, herpes simplex virus and human immunodeficiency 
have all been described.3 In addition, several bacterial (Salmonella 
typhi, mycobacterium, rickettsia, brucellosis and mycoplasma 
infections), protozoal, parasitic (malaria and leishmaniasis) and rarely 
fungal organisms (histoplasmosis) have been implicated.3
Diagnosis of this condition is based on a combination of clinical and 
laboratory findings as described in HLH Guidelines: HLH-2004.4 
Based on these guidelines a diagnosis of HLH can be made if one or both 
of the following criteria are present: (i) a molecular diagnosis consistent 
with HLH; or (ii) five of the eight diagnostic criteria for HLH.5  
The eight HLH diagnostic criteria include fever, splenomegaly, 
cytopenias (affecting two of three lineages in the peripheral 
blood: haemoglobin <9 g/dl in patients ≥4 weeks old and <10 g/
dl in patients <4 weeks, platelets <100 x 109/l, neutrophils <1.0 x 
109/l), hypertriglyceridaemia (fasting triglycerides >3.0 mmol/l) or 
hypofibrinogenaemia (fibrinogen <1.5 g/l), haemophagocytosis in 
bone marrow, spleen or lymph nodes with no evidence of malignancy, 
low or absent NK cell activity (according to local laboratory 
reference), elevated ferritin (ferritin >500 mg/l) and soluble CD25 
(i.e. soluble interleukin-2 receptor) above the normal limit for age.4,5
We report a case of a 26-month-old boy with HLH secondary to 
pneumococcal infective endocarditis of his tricuspid valve which to 
our knowledge has not been previously described. 
Case report
A 2-year-old boy was referred to a tertiary referral centre with a 
3-week history of fever, anorexia, loss of weight and associated 
intermittent vomiting and diarrhoea. He had no history of coughing, 
bone pain, bruising or bleeding.
He was fully immunised, although it is noteworthy that prior to his 
presentation conjugate pneumococcal vaccine was not yet included in 
the South African national immunisation schedule. 
On examination he was pyrexial (39.5°C), underweight for age 
and stunted. He was markedly pale and noted to have peri-orbital 
oedema. He had no skin rashes or significant lymphadenopathy. 
He was tachycardic (140 beats/min) with a grade 3/6 pansystolic 
murmur audible at the lower left sternal border, a palpable 6 cm, firm 
hepatomegaly and a firm 3 cm splenomegaly. Urine dipstix did not 
show microscopic haematuria and there were no other stigmata of 
sub-acute bacterial endocarditis.
His full blood count showed a bicytopenia and severe microcytic 
anaemia (Hb 4.5 g/dl and MCV 59.6 fl; platelets 31 x 109/l).  His 
86        SAJCH  AUGUST 2012  Vol. 6  No. 3
CASE REPORT
white blood count was normal (18.8 x 109/l). The 
differential count showed a marked left shift with 
toxic granulation and no blasts. His corrected 
reticulocyte count was inappropriately low for 
his haemoglobin (1.39%). HIV ELISA was non-
reactive. Serum C-reactive protein was elevated at 
180 mg/l. Iron studies were done to confirm the 
diagnosis of iron deficiency. The serum ferritin 
was markedly raised (6 502 µg/l). Coagulation 
studies revealed a low serum fibrinogen (1.0 
g/l) with a normal INR and PTT. His serum 
triglycerides were markedly elevated at 4.6 (1.1 
- 1.9 mmol/l). His initial LDH was 643 mmol/l 
(ALT 39 U/l) and he had an ESR of 25 mm/hr.
Epstein-Barr virus IgM was negative. Epstein-
Barr viral load was 1 607 copies/ml, log value 3.21 
(within acceptable limits for our population). A 
chest X-ray showed an increased cardiothoracic 
index. There was no significant hilar adenopathy 
and the lung fields were clear. An abdominal 
ultrasound confirmed a radiologically enlarged 
spleen with no focal lesions, adenopathy or ascites. A bone marrow 
aspirate and trephine revealed a marked infiltration of CD 68 
positive histiocytes with evidence of haemophagocytosis. A lumbar 
puncture was not done because there was no suspicion of central 
nervous system involvement.
Initially he was commenced on intravenous ceftriaxone 50 mg/
kg daily and transfused with blood and platelets. After 5 days 
he was changed to piperacillin tazobactam and amikacin when 
the temperature did not settle. He fulfilled seven of the eight 
criteria for diagnosis of HLH: documented fever, splenomegaly, 
severe bicytopenia, hyperferritinaemia, hypofibrinogenaemia and 
hypertriglyceridaemia and haemophagocytosis on bone marrow 
biopsy with no evidence of leukaemia. Assays for soluble CD 25 and 
NK cell activity are not available at our institution.
Intravenous dexamethasone at 10 mg/m2  was commenced.  It is our 
practice to reserve intravenous etoposide and oral cyclosporine for 
proven EBV-driven HLH.
The diagnosis of HLH was made 8 days after presentation. There 
was a dramatic clinical response to dexamethasone. His subsequent 
markers are shown in Table 1. Antibiotic therapy 
was stopped after his temperature settled and 
cultures remained negative. 
The cardiac murmur that had been noted on 
admission was initially thought to be secondary 
to a hyperdynamic circulation due to his marked 
anaemia and pyrexia.  It persisted despite 
transfusions and dexamethasone. This prompted 
us to do an echocardiogram which revealed a 6 
mm peri-membranous ventricular septal defect 
(VSD) and large 16 x 22 mm vegetation on the 
tricuspid valve. He was recommenced on triple 
antibiotic therapy with intravenous penicillin G, 
cloxacillin and gentamicin. Prior to administration 
of these antibiotics his blood grew Streptococcus 
pneumoniae which was sensitive to penicillin. After 
commencement of triple antibiotics, a Portocath 
was inserted because of poor venous access. Two 
days later the vegetation was surgically removed 
and an anterior valvuloplasty was performed 
under cardiac bypass. Histopathology confirmed 
gram-positive cocci focally in chains within the vegetation.
Postoperatively he developed a pericardial effusion which resolved 
with diuretic therapy and did not necessitate pericardiocentesis. 
Triple antibiotic therapy was continued for 2 weeks, after which 
gentamicin was stopped. Penicillin G and cloxacillin were continued 
for a total of 26 days. Subsequently, the Portocath became infected 
with culture-proven Klebsiella pneumoniae sensitive to meropenem. 
He received appropriate intravenous therapy for 10 days after 
immediate removal of the device.
Dexamethasone was continued throughout for a total of 8 weeks. 
The dose was halved every 2 weeks, tapered and then stopped. 
He has now been followed up by both the Cardiology and 
Haematology/Oncology teams for 18 months, since stopping 
dexamethasone. Ferritin, fibrinogen and triglyceride levels have 
remained normal, as have his blood count (Table 1). Follow-up 
echocardiograms show marked residual tricuspid regurgitation 
and a small restrictive VSD for which he receives maintenance 
oral diuretic therapy. He continues to grow well and remains in 
the care of the cardiology services. A tricuspid valve replacement 
is planned for the future.
Table 1.  Blood investigations over the course of treatment
Date WBC Haemoglobin Platelets Fibrinogen Triglycerides Ferritin
At diagnosis 19.6 4.5 45 1.0 1 502
Week 1 26.4 10.4 72 4.6
Week 2 53.3 10.7 213 0.8 2.9 964
Week 3 14.8 10.9 356 4.4 1.7 245
Week 5 8.6 12.8 463 2.2 1.8 139
Week 6 16 13.4 Clumped 3.1 1.9 213
Week 16 10.6 11.9 283 4.1 1.0 125
Week 20 12.6 12.9 482 3.8 2.7 151
Week 25 9.5 12.4 400 3.3 1.4 97
Week 46 9.3 12.4 340
Week 58 8.7 13.7 274
Week 79 9.5 12.2 309
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Streptococcus pneumoniae is a common pathogen in paediatrics, known 
to be the primary cause of many respiratory tract infections. Despite 
this, we could not fi nd any reports of the organism being implicated 
as a causative infection for triggering secondary HLH. 
Th is young patient was an immuno-competent child. Streptococcus 
pneumoniae was cultured on his initial blood culture and confi rmed 
with the histological fi nding of gram-positive cocci in chains in 
the vegetation removed from his tricuspid valve. From this we 
concluded it must have been the infection that precipitated his 
HLH.
Right-sided infective endocarditis is not common in children with 
structurally normal hearts and those who do not have indwelling 
central venous lines.  For this reason we would not have initially 
expected this condition in our patient. Th e fi nding of a previously 
undiagnosed small, peri-membranous VSD on echocardiogram in 
this patient, however, off ers an explanation as to why his tricuspid 
valve was involved. Alterations to intracardiac blood fl ow caused 
by VSDs are known to make these patients more susceptible to 
infective endocarditis involving the tricuspid valve.6 Streptococci and 
staphylococci remain the most common causative organisms.
Current management guidelines for the treatment of HLH 
recommend the use of a combination dexamethasone, etoposide and 
cyclosporine (HLH 2004) as fi rst-line therapy. Fully cognisant of the 
fact that single-agent therapy for HLH is not ideal or recommended,3 
the socio-economic environment of many of our patients, the high 
incidence of tuberculosis and HIV infection, and the high cost of 
cyclosporin justifi ed an informed institutional policy decision to 
treat only proven EBV-driven HLH with cyclosporine and etoposide 
upfront along with dexamethasone. Outside of this we reserve the 
use of the former two agents for refractory or relapsed disease.  All 
other patients with secondary HLH get dexamethasone alone. We 
have had suffi  cient success with this strategy to believe that it has a 
role to play in our setting.
References
1. Imashuku S, Hibi S, Todo S. Hemophagocytic lymphohistiocytosis in infancy 
and childhood. J Pediatr 1997;130(3):352-357. [http://dx.doi.org/10.1016/
S0022-3476(97)70195-1] [PMID: 9063408]
2. Gholam C, Grigoriadou S, Gilmour KC, et al. Familial haemophagocytic 
lymphohistiocytosis: advances in the genetic basis, diagnosis and management. 
Clin Exp Immunol 2011;163(3):271-283. [http://dx.doi.org/10.1111/j.1365-
2249.2010.04302.x] [PMID: 21303357]
3. Fisman D. Hemophagocytic syndromes and infection. Emerg Infect Dis 
2000;6(6):601-608. [http://dx.doi.org/10.3201/eid0606.000608] [PMID: 
11076718]                                   
4. Henter J-I, Horne A, Arico M, et al. HLH-2004. Diagnostic and therapeutic 
guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 
2007;48(2):124-131.[http://dx.doi.org/10.1002/pbc21039][PMID: 
16937360]
5. Filipovich AH. Hemophagocytic lymphocytosis and other hemophagocytic 
disorders. Immunol Allergy Clin North Am 2008;28(2):293-313.  
[http://dx.doi.org/10.1016/j.iac.2008.01.010] [PMID: 18424334]
6. Di Fillipo S, Semiond B, Celard M, et al Characteristics of infectious 
endocarditis in ventricular septal defects in children and adults. Arch Mal 
Coeur Vaiss 2004;97(5):507-514. [PMID: 1521455]
